Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Core Insights - Fractyl Health, Inc. is focused on innovative metabolic therapeutics aimed at addressing the root causes of obesity and type 2 diabetes (T2D) [1][3] - The company will present preclinical data on its Rejuva gene therapy platform at the ASGCT 2025 Annual Meeting [1][2] Company Overview - Fractyl Health is dedicated to transforming the treatment of metabolic diseases from chronic management to durable, disease-modifying therapies [3] - The company is based in Burlington, Massachusetts, and aims to tackle the increasing morbidity and mortality associated with obesity and T2D [3] Rejuva Platform - The Rejuva platform is developing AAV-based gene therapies specifically targeting obesity and T2D, currently in preclinical development [4] - The platform utilizes advanced delivery systems and proprietary screening methods to identify effective gene therapy candidates [4] - The company plans to submit a Clinical Trial Application (CTA) for RJVA-001 in T2D in the first half of 2025, with preliminary data expected in 2026 if authorized [4]